- Home
- ENTG vs BMRN Comparison
ENTG vs BMRN Comparison
Compare ENTG & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ENTG | BMRN |
|---|---|---|
| Founded | 1966 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1B | 10.5B |
| IPO Year | 2000 | 1999 |
Fundamental Metrics
Financial Performance| Metric | ENTG | BMRN |
|---|---|---|
| Price | $76.61 | $55.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 18 |
| Target Price | ★ $98.25 | $90.00 |
| AVG Volume (30 Days) | 2.7M | ★ 3.1M |
| Earning Date | 10-30-2025 | 10-27-2025 |
| Dividend Yield | ★ 0.52% | N/A |
| EPS Growth | 26.59 | ★ 59.53 |
| EPS | 1.90 | ★ 2.68 |
| Revenue | ★ $3,222,508,000.00 | $3,094,001,000.00 |
| Revenue This Year | $0.33 | $13.32 |
| Revenue Next Year | $6.33 | $7.51 |
| P/E Ratio | $40.61 | ★ $20.86 |
| Revenue Growth | 0.59 | ★ 12.39 |
| 52 Week Low | $60.75 | $50.76 |
| 52 Week High | $112.36 | $73.51 |
Technical Indicators
Market Signals| Indicator | ENTG | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 43.09 | 57.07 |
| Support Level | $72.23 | $54.51 |
| Resistance Level | $75.13 | $56.45 |
| Average True Range (ATR) | 3.56 | 1.53 |
| MACD | -0.13 | 0.28 |
| Stochastic Oscillator | 42.75 | 81.90 |
Price Performance
Historical ComparisonAbout ENTG Entegris Inc.
Entegris is a leading supplier of purification solutions and advanced materials. The vast majority of sales are to the semiconductor industry. The majority of revenue comes from semiconductor fabricators, but the company sells to all areas of the semiconductor manufacturing supply chain including equipment and engineering, chemicals and materials, and distributors. Entegris specializes in materials science and materials purity, both of which are crucial in the semiconductor manufacturing process.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.